青岛双星(000599) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 1,134,729,819.67, a decrease of 3.89% compared to CNY 1,180,623,058.62 in the same period last year[5] - The net profit attributable to shareholders was a loss of CNY 104,307,903.27, representing a decline of 382.86% from a loss of CNY 21,601,923.79 in the previous year[5] - The company reported a basic and diluted earnings per share of -CNY 0.13, a decrease of 333.33% from -CNY 0.03 in the previous year[5] - The company's operating profit for the current period was -99,355,711.60 yuan, compared to -35,765,188.60 yuan in the previous period, indicating a significant decline in profitability[19] - Net profit attributable to the parent company was -104,307,903.27 yuan, a decrease from -21,601,923.79 yuan year-over-year[20] - The total comprehensive income for the current period was -102,620,446.22 yuan, compared to -36,284,360.27 yuan in the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 80.82%, amounting to CNY 23,182,593.81 compared to CNY 120,878,762.94 in the same period last year[5] - The net cash flow from financing activities increased by 187.40%, amounting to CNY 307,421,470.85, primarily due to new borrowings[10] - Cash flow from operating activities generated a net cash inflow of 23,182,593.81 yuan, down from 120,878,762.94 yuan in the previous period[22] - The company’s cash and cash equivalents at the end of the period totaled 582,410,942.38 yuan, down from 666,737,918.80 yuan at the end of the previous period[22] - Cash and cash equivalents increased to CNY 1,042,976,569.60 from CNY 877,268,677.52, representing an increase of 18.8%[15] Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,172,367,825.37, an increase of 0.62% from CNY 9,115,681,318.13 at the end of the previous year[5] - Current assets totaled CNY 3,185,269,647.35, slightly up from CNY 3,177,905,564.03 at the beginning of the period[16] - Total liabilities increased to CNY 7,546,376,236.63 from CNY 7,387,422,590.53, marking a rise of 2.2%[17] - The company's total assets amounted to CNY 9,172,367,825.37, up from CNY 9,115,681,318.13, reflecting an increase of 0.6%[17] - The total equity attributable to shareholders decreased to CNY 1,488,931,364.69 from CNY 1,595,334,392.42, a decline of 6.7%[17] Operational Highlights - The company adjusted its domestic TBR product structure, resulting in a 20% increase in revenue from TBR products compared to the previous year[9] - The revenue from the Cambodian factory's TBR production reached CNY 1.77 billion in Q1, contributing to improved profitability[9] - The company plans to optimize PCR capacity and leverage the advantages of the Cambodian factory to enhance overall profitability[9] Costs and Expenses - Total operating costs increased to CNY 1,279,267,266.03, up from CNY 1,250,523,819.18, reflecting a rise of 2.2%[18] - Research and development expenses increased to 38,881,210.63 yuan from 30,703,475.31 yuan, reflecting a 26.6% increase year-over-year[19] - The company incurred financial expenses of 34,088,443.70 yuan, down from 42,553,215.17 yuan, showing a reduction of approximately 19.9%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,012[12] - The basic and diluted earnings per share were both -0.13 yuan, compared to -0.03 yuan in the previous period[20]